Maurilio Garcia-Gil, MD
Urology · San Antonio, TXNPI 1881008613
Payments from drug & device makers
What this record shows
This record is dominated by grants: $25,000 of the $35,729 with a category attached, or 70.0%. Boston Scientific accounts for 73.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $25,564 and has fallen 65.3% since, to $8,880 in 2025. Among urology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $700.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$26K
- Calyxo, Inc.$6K
- Olympus America Inc.$3K
- Cook Medical LLC$156
- Astellas Pharma US Inc$142
- Johnson & Johnson$68
- plus $296 from 10 others
Across 6 payments — averaging $43,394 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Provepharm Inc.$260K
What the payments were for
- Consulting fees$7,87022%
- Grants$25,00070%
- Travel & lodging$1,3564%
- Food & beverage$1,4094%
- Education$940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 10 | $26,129 |
| Calyxo, Inc. | 12 | $5,562 |
| Olympus America Inc. | 4 | $3,375 |
| Cook Medical LLC | 2 | $156 |
| Astellas Pharma US Inc | 4 | $142 |
| Johnson & Johnson | 4 | $68 |
| Dendreon Pharmaceuticals LLC | 2 | $59 |
| Myriad Genetic Laboratories, Inc. | 2 | $40 |
| Ferring Pharmaceuticals Inc. | 1 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Urovant Sciences Inc | 1 | $32 |
| AbbVie | 1 | $26 |
| Travere Therapeutics, Inc. | 3 | $20 |
| Acell, Inc. | 1 | $20 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$25,000
- Soltive$6,720
- CVAC Aspiration System$5,453
- SWISS LITHOCLAST TRILOGY$152
- Cook Medical Stents$101
How this compares
$35,729 in reported general payments places this provider in the 90th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 68 | $183,429 |
| GemtesaVibegron | 148 | $177,369 |
| MyrbetriqMirabegron | 128 | $124,266 |
| Thiola EcTiopronin | 12 | $91,001 |
| ThiolaTiopronin | 13 | $32,879 |
| Estradiol | 110 | $9,093 |
| Tamsulosin Hcl | 548 | $4,094 |
| Trospium Chloride ErTrospium Chloride | 13 | $3,412 |
| Potassium Citrate ErPotassium Citrate | 41 | $3,372 |
| Finasteride | 351 | $3,151 |
| Oxybutynin Chloride ErOxybutynin Chloride | 208 | $3,055 |
| Solifenacin Succinate | 17 | $1,218 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 71 | $1,071 |
| NitrofurantoinNitrofurantoin Macrocrystal | 18 | $655 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 33 | $620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $34 | $360,797216 claims |
| Astellas Pharma US IncMyrbetriq | $142 | $124,266128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 urology providers in Texas.
Other urology in San Antonio
- Daniel SaltzsteinSan Antonio$547K
- Leroy JonesSan Antonio$506K
- Jose de la CerdaSan Antonio$278K
- Naveen KellaSan Antonio$84K
- Christopher CantrillSan Antonio$73K
- Robert SvatekSan Antonio$51K
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
- Arun RaiHouston$920K
- Allen MoreyDallas$914K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.